Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22878864 | 1.00 | P2RX7 (0.71) | P2RX7 | |
| Water SCHEMBL492139 | 0.99 | P2RX7 (0.70) | P2RX7 | |
| SCHEMBL491734 | 0.87 | P2RX7 (0.60) | P2RX7 | |
| SCHEMBL1802127 | 0.86 | P2RX7 (0.82) | P2RX7 | |
| SCHEMBL491653 | 0.85 | P2RX7 (0.71) | P2RX7 | |
| Hydrochloric Acid SCHEMBL3839613 | 0.85 | P2RX7 (0.81) | P2RX7 | |
| SCHEMBL17327671 | 0.84 | P2RX7 (0.65) | P2RX7 | |
| SCHEMBL17327643 | 0.83 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL4176834 | 0.83 | P2RX7 (0.55) | P2RX7 | |
| SCHEMBL3837373 | 0.82 | P2RX7 (0.75) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-30 | — | — | US | disclosed |
| EP-3402469-B1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INST NAT SANTE RECH MED (FR) | 2021-01-06 | — | — | EP | disclosed |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale (FR) | 2020-02-04 | — | — | US | disclosed |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2019-01-24 | — | — | US | disclosed |
| WO-2017121840-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-07-20 | — | — | WO | disclosed |
| US-8106073-B2 | Quinoline derivatives 057 | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-8106073-B2 | Quinoline derivatives 057 | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-8106073-B2 | Quinoline derivatives 057 | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| EP-2225222-B1 | A QUINOLINE DERIVATIVE ACTING AS A P2X7-RECEPTOR ANTAGONIST | ASTRAZENECA AB (SE) | 2011-09-14 | — | — | EP | disclosed |
| EP-2225222-B1 | A QUINOLINE DERIVATIVE ACTING AS A P2X7-RECEPTOR ANTAGONIST | ASTRAZENECA AB (SE) | 2011-09-14 | — | — | EP | disclosed |
| US-20090143428-A1 | Quinoline Derivatives 057 | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143428-A1 | Quinoline Derivatives 057 | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143428-A1 | Quinoline Derivatives 057 | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| WO-2009070116-A1 | A QUINOLINE DERIVATIVE ACTING AS A P2X7-RECEPTOR ANTAGONIST | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | P2RX7 12/4885 |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885 |
| US-20090143428-A1 | Quinoline Derivatives 057 | CYP3A7, UGT1A7, UGT2B7 | P2RX7 64/4885 |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | STING1, IRF3, CGAS | P2RX7 14/4885 |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.